Epidemiology of Invasive Pneumococcal Disease in Bangladeshi Children Before Introduction of Pneumococcal Conjugate Vaccine

Background: Because Bangladesh intended to introduce pneumococcal conjugate vaccine (PCV)-10 in 2015, we examined the baseline burden of invasive pneumococcal disease (IPD) to measure impact of PCV. Methods: During 2007–2013, we performed blood and cerebrospinal fluid cultures in children <5 years old with suspected IPD identified through active surveillance at 4 hospitals. Isolates were serotyped by quellung and tested for antibiotic susceptibility by disc diffusion and E-test. Serotyping of culture-negative cases, detected by Binax or polymerase chain reaction, was done by sequential multiplex polymerase chain reaction. Trends in IPD case numbers were analyzed by serotype and clinical syndrome. Results: The study identified 752 IPD cases; 78% occurred in children <12 months old. Serotype information was available for 78% (442/568), including 197 of 323 culture-negative cases available for serotyping. We identified 50 serotypes; the most common serotypes were 2 (16%), 1 (10 %), 6B (7%), 14 (7%) and 5 (7%). PCV-10 and PCV-13 serotypes accounted for 46% (range 29%–57% by year) and 50% (range 37%–64% by year) of cases, respectively. Potential serotype coverage for meningitis and nonmeningitis cases was 45% and 49% for PCV-10, and 48% and 57% for PCV-13, respectively. Eighty-two percent of strains were susceptible to all antibiotics except cotrimoxazole. Conclusion: The distribution of serotypes causing IPD in Bangladeshi children is diverse, limiting the proportion of IPD cases PCV can prevent. However, PCV introduction is expected to have major benefits as the country has a high burden of IPD-related mortality, morbidity and disability.

[1]  K. Mølbak,et al.  Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  B. Flannery,et al.  Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. , 2014, The Lancet. Respiratory medicine.

[3]  K. O'Brien,et al.  Dosing Schedules for Pneumococcal Conjugate Vaccine , 2013, The Pediatric infectious disease journal.

[4]  V. Balaji,et al.  Invasive pneumococcal infections in Vellore, India: clinical characteristics and distribution of serotypes , 2013, BMC Infectious Diseases.

[5]  T. Cherian,et al.  Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites , 2013, PLoS medicine.

[6]  S. Madhi,et al.  Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. , 2013, Vaccine.

[7]  S. Schrag,et al.  Sentinel versus population-based surveillance of pneumococcal conjugate vaccine effectiveness. , 2012, Bulletin of the World Health Organization.

[8]  T. Tan Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines , 2012, Clinical Microbiology Reviews.

[9]  A. Chandran,et al.  The Worldwide Impact of the Seven-valent Pneumococcal Conjugate Vaccine , 2012, The Pediatric infectious disease journal.

[10]  A. Naheed,et al.  Streptococcus pneumoniae Serotype-2 Childhood Meningitis in Bangladesh: A Newly Recognized Pneumococcal Infection Threat , 2012, PloS one.

[11]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[12]  N. Andrews,et al.  Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. , 2011, The Lancet. Infectious diseases.

[13]  J. Verhaegen,et al.  Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. , 2011, Vaccine.

[14]  J. Al-Tawfiq,et al.  Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections , 2011, Expert review of vaccines.

[15]  Scott Williams,et al.  Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7‐valent pneumococcal conjugate vaccine , 2011, The Medical journal of Australia.

[16]  K. O'Brien,et al.  Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project , 2010, PLoS medicine.

[17]  G. Gilbert,et al.  Identification of Newly Described Streptococcus pneumoniae Serotype 6D by Use of the Quellung Reaction and PCR , 2010, Journal of Clinical Microbiology.

[18]  B. Beall,et al.  Serotype-Specific Typing Antisera for Pneumococcal Serogroup 6 Serotypes 6A, 6B, and 6C , 2010, Journal of Clinical Microbiology.

[19]  F. Sorvillo,et al.  Declining invasive pneumococcal disease mortality in the United States, 1990-2005. , 2010, Vaccine.

[20]  O. Levine,et al.  Sequelae due to bacterial meningitis among African children: a systematic literature review , 2009, BMC medicine.

[21]  T. Cherian,et al.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates , 2009, The Lancet.

[22]  F. Kong,et al.  Simple, Accurate, Serotype-Specific PCR Assay To Differentiate Streptococcus pneumoniae Serotypes 6A, 6B, and 6C , 2009, Journal of Clinical Microbiology.

[23]  N. Khan,et al.  Neurodevelopmental sequelae in pneumococcal meningitis cases in Bangladesh: a comprehensive follow-up study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Scott,et al.  Enhanced diagnosis of pneumococcal meningitis with use of the Binax NOW immunochromatographic test of Streptococcus pneumoniae antigen: a multisite study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Naheed,et al.  Surveillance for invasive Streptococcus pneumoniae disease among hospitalized children in Bangladesh: antimicrobial susceptibility and serotype distribution. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Murdoch,et al.  Hospital-based surveillance of invasive pneumococcal disease among young children in urban Nepal. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  M. Steinhoff,et al.  Invasive pneumococcal disease in Kanti Children's Hospital, Nepal, as observed by the South Asian Pneumococcal Alliance network. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  A. Naheed,et al.  Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  R. Dagan,et al.  Impact of conjugate pneumococcal vaccines on antibiotic resistance. , 2008, The Lancet. Infectious diseases.

[30]  A. Naheed,et al.  Identification of Serotype in Culture Negative Pneumococcal Meningitis Using Sequential Multiplex PCR: Implication for Surveillance and Vaccine Design , 2008, PloS one.

[31]  Steven D. Brown,et al.  Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4 , 2008, Annals of Clinical Microbiology and Antimicrobials.

[32]  A. Naheed,et al.  Invasive pneumococcal disease burden and implications for vaccine policy in urban Bangladesh. , 2007, The American journal of tropical medicine and hygiene.

[33]  K. O'Brien,et al.  Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. , 2007, The Journal of infectious diseases.

[34]  S. Richter,et al.  Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[35]  D. Lehmann,et al.  Pneumococcal vaccination in developing countries , 2006, The Lancet.

[36]  D. Hamer,et al.  Rapid Diagnosis of Pneumococcal Meningitis: Implications for Treatment and Measuring Disease Burden , 2005, The Pediatric infectious disease journal.

[37]  J. Kremastinou,et al.  Simultaneous single-tube PCR assay for the detection of Neisseria meningitidis, Haemophilus influenzae type b and Streptococcus pneumoniae. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[38]  S. Obaro,et al.  Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial , 2005, The Lancet.

[39]  K. Ko,et al.  High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study) , 2004, Antimicrobial Agents and Chemotherapy.

[40]  R. Black,et al.  Comparison of Antibiotic Resistance and Serotype Composition of Carriage and Invasive Pneumococci among Bangladeshi Children: Implications for Treatment Policy and Vaccine Formulation , 2003, Journal of Clinical Microbiology.

[41]  J. Garau Treatment of drug-resistant pneumococcal pneumonia. , 2002, The Lancet. Infectious diseases.

[42]  R. Sack,et al.  Antimicrobial Resistance and Serotype Distribution of Streptococcus pneumoniae Strains Causing Childhood Infections in Bangladesh, 1993 to 1997 , 1999, Journal of Clinical Microbiology.

[43]  R. Sack,et al.  Serotypes of Streptococcus pneumoniae causing invasive childhood infections in Bangladesh, 1992 to 1995 , 1997, Journal of clinical microbiology.

[44]  M. Cheesbrough Medical Laboratory Manual for Tropical Countries , 1991 .

[45]  J. Jorgensen,et al.  Quantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae by using the E-test , 1991, Journal of clinical microbiology.

[46]  A. Walker,et al.  Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. , 2011, Journal of medical microbiology.

[47]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[48]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .